General MedicationsORALGeneric
FANSIDAR
PYRIMETHAMINE; SULFADOXINE
Standard Dose
25MG;500MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview FANSIDAR is listed in Drugs@FDA under application 018557 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient PYRIMETHAMINE; SULFADOXINE Form and strength TABLET;ORAL - 25MG;500MG Sponsor ROCHE Submission history Latest submission status date: 2004-02-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview FANSIDAR is listed in Drugs@FDA under application 018557 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient PYRIMETHAMINE; SULFADOXINE Form and strength TABLET;ORAL - 25MG;500MG Sponsor ROCHE Submission history Latest submission status date: 2004-02-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.